Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer.
Tsaur I, Heidegger I, Bektic J, Kafka M, van den Bergh RCN, Hunting JCB, Thomas A, Brandt MP, Höfner T, Debedde E, Thibault C, Ermacora P, Zattoni F, Foti S, Kretschmer A, Ploussard G, Rodler S, von Amsberg G, Tilki D, Surcel C, Rosenzweig B, Gadot M, Gandaglia G, Dotzauer R; EAU-YAU Prostate Cancer Working Party. Tsaur I, et al. Among authors: brandt mp. Cancer Med. 2021 Sep;10(18):6354-6364. doi: 10.1002/cam4.4184. Epub 2021 Aug 10. Cancer Med. 2021. PMID: 34374489 Free PMC article.
Docetaxel-rechallenge in castration-resistant prostate cancer: defining clinical factors for successful treatment response and improvement in overall survival.
Thomas C, Brandt MP, Baldauf S, Tsaur I, Frees S, Borgmann H, Jäger W, Bartsch G, Schneider M, Dotzauer R, Neisius A, Haferkamp A. Thomas C, et al. Among authors: brandt mp. Int Urol Nephrol. 2018 Oct;50(10):1821-1827. doi: 10.1007/s11255-018-1963-1. Epub 2018 Aug 17. Int Urol Nephrol. 2018. PMID: 30120678
Immunotherapy in prostate cancer: new horizon of hurdles and hopes.
Tsaur I, Brandt MP, Juengel E, Manceau C, Ploussard G. Tsaur I, et al. Among authors: brandt mp. World J Urol. 2021 May;39(5):1387-1403. doi: 10.1007/s00345-020-03497-1. Epub 2020 Oct 26. World J Urol. 2021. PMID: 33106940 Free PMC article. Review.
Predictors of Unfavorable Pathology in Patients with Incidental (pT1a-T1b) Prostate Cancer.
Tsaur I, van den Bergh RCN, Soeterik T, Thomas A, Brandt MP, Zattoni F, Dal Moro F, Morlacco A, Collavino J, Ploussard G, Surcel C, Mirvald C, Carmona O, Rosenzweig B, Ruckes C, Heisinger T, Heidegger I, Gandaglia G, Dotzauer R; European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Tsaur I, et al. Among authors: brandt mp. Eur Urol Focus. 2022 Nov;8(6):1599-1606. doi: 10.1016/j.euf.2022.03.009. Epub 2022 Mar 19. Eur Urol Focus. 2022. PMID: 35317972
Focal therapy for primary tumor and metastases in de novo or recurrent oligometastatic prostate cancer: current standing and future perspectives.
Tsaur I, Blaheta RA, Dotzauer R, Brandt MP, Gandaglia G, Sinescu I, Mirvald C, Olivier J, Surcel C; EAU-YAU Prostate Cancer Working Party. Tsaur I, et al. Among authors: brandt mp. World J Urol. 2023 Aug;41(8):2077-2090. doi: 10.1007/s00345-022-04162-5. Epub 2022 Oct 2. World J Urol. 2023. PMID: 36183289 Review.
Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
Puhr M, Eigentler A, Handle F, Hackl H, Ploner C, Heidegger I, Schaefer G, Brandt MP, Hoefer J, Van der Pluijm G, Klocker H. Puhr M, et al. Among authors: brandt mp. Oncogene. 2021 Apr;40(17):3087-3100. doi: 10.1038/s41388-021-01754-0. Epub 2021 Apr 1. Oncogene. 2021. PMID: 33795839 Free PMC article.
46 results